Accolade Secures $71.1M Series E Funding to Advance Personalized Health Assistant Platform

By Liu Lushi

Technological innovation is driving the transformation and upgrading of the healthcare industry. Accolade, a medical technology platform company, is leveraging its healthcare technology and services platform to provide “expert health assistant” services to corporate employers, medical institutions, and health systems. Recently, Accolade secured $71.1 million in Series E funding, which will be used to continuously optimize and upgrade its healthcare service platform.

Accolade, founded in 2007 and headquartered in Plymouth Meeting, Pennsylvania, currently has 700 employees. This low-profile company is not widely known; even Accolade’s CEO, Rajeev Singh, has stated, “We are the best-kept secret in healthcare.” However, its recent financing round of over $70 million has significantly boosted Accolade’s visibility. The funding came from two venture capital firms: Andreessen Horowitz and Madrona Venture Group. To date, Accolade has completed seven financing rounds, with total funding exceeding $163 million.

Following this financing round, Accolade will add Jeff Jordan, general partner at Andreessen Horowitz and former CEO of the OpenTable dining platform, to its board of directors.

AccoladeFinancing Status,Series E Funding Exceeds $70 Million

Accolade defines itself as a company providing professional health assistant services, with its core being the “Accolade Health Assistants™” platform, which comprehensively collects user information and, based onMedical analytics tools and clinical models to provide patients with personalized consultation and diagnosis.When users have medical needs, they can directly contact the “Health Assistant” via telephone, mobile app, or PC web portal. Behind each “Health Assistant” is a team of qualified medical support professionals, such as nurses, physicians, pharmacists, medical social workers, and medical specialists.

Whether it’s finding specialists, analyzing medical bills, consulting on optimal treatment plans, or alerting family members to potential symptoms of diabetes, Accolade delivers patient services directly through its “Health Assistants,” guiding users on next steps—such as which medications to take and where to seek care—thereby sparing patients the hassle of seeking medical help without clear direction. By maintaining engagement at every stage of users’ treatment and consultation journeys, Accolade fosters growing trust in its platform.

Users can consult the health assistant directly via the app or website.

In early August this year, Accolade partnered with Mercer to launch the “Mercer Complete Care” program, which aims to enhance corporate benefits, create a better healthcare experience for employees, improve employee health outcomes, and boost long-term corporate performance. By integrating their respective healthcare resources—combining Accolade’s user base and health technology infrastructure with Mercer’s industry insights and enterprise client portfolio—the two companies seek to address the confusion employees face when navigating healthcare consultations, streamline treatment processes, and set new standards for healthcare services.

The company's model is data-driven+Technology as Strategy: When Providing Medical Services to Patients, on the One Hand, ThroughAccolade The platform collects extensive medical record data and health insurance information from patients and even their families, while on the other hand, itAccolade Medical professionals on the platform leverage their extensive personal clinical experience, combined with data analysis, to conduct diagnosis and treatment.

Compared with traditional medical services, Accolade’s healthcare technology platform offers significant advantages in both cost and treatment outcomes. This is because the platform provides customized analysis of each user’s condition, automatically screens treatment options, eliminates unnecessary procedures, and presents the most cost-effective choices. According to Accolade, its services can reduce patients’ healthcare expenses by 5%–15%.

Outstanding Results: Among the 70% of the eligible population, 98% reported satisfaction, with a 10% reduction in healthcare costs.

Rajeev Singhstated,Accolade By building connections with users and leveraging the hospital’s proprietary medical analytics tools and clinical models, we achieve a comprehensive, data-driven representation of patients’ health status. This approach enhances the personalization of medical services and boosts user engagement, representing an innovation across the entire healthcare sector.He further added that leveraging data to build personalized health models for users, delivering humanized services and efficient clinical diagnostics, and integrating patient engagement strategies are key to next-generation healthcare services.

The Accolade platform aligns perfectly with the three core standards of the Institute for Healthcare Improvement (IHI): better care, better health, and lower costs. Users enjoy a positive experience with human-centric healthcare services on the platform, leading to improved health outcomes and a continuous reduction in treatment expenses.

Accolade CEO Rajeev Singh, the company’s innovative healthcare analytics tools and clinical models

Rajeev Singh joined the Accolade team last year, having previously spent 22 years at Concur Technologies, the travel management company he founded and which was later acquired by SAP. When asked about his reasons for joining, Singh stated that Accolade’s integration of people, networks, and healthcare is quite compelling.

Investors appear to be interested in Accolade for similar reasons. Jeff Jordan, a partner at the venture capital firm Andreessen Horowitz, stated, “The Accolade platform helps enterprises enhance the quality of their healthcare benefits while continuously reducing medical costs. It is, to our knowledge, the finest healthcare service tool available.” Accolade indicated that it would allocate the new funding toward improving its technology platform, investing in medical research, and expanding its market presence.